Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MMONARCh-1: Study of MSDC-0602K, a Modulator of the Mitochondrial Pyruvate Carrier for Outcomes in Patients With Pre Type 2 Diabetes (T2D) or T2D and NAFLD/NASH, Assessed for ImpRoved Glycemic Control and Cardiovascular Outcomes-1

NCT03970031 is registered in ClinicalTrials.gov with Cirius Therapeutics, Inc. as lead sponsor.

NCT NCT03970031
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03970031 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MMONARCh-1: Study of MSDC-0602K, a Modulator of the Mitochondrial Pyruvate Carrier for Outcomes in Patients With Pre Type 2 Diabetes (T2D) or T2D and NAFLD/NASH, Assessed for ImpRoved Glycemic Control and Cardiovascular Outcomes-1
Lead sponsor
Cirius Therapeutics, Inc.
Phase
Phase 3
Overall status
Unknown status
Start date
June 30, 2022
Completion date
September 30, 2024
Enrollment
1,800 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

nash - nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type2 diabetes